Merck KGaA (OTCMKTS:MKKGY - Get Free Report) saw a large increase in short interest in October. As of October 15th, there was short interest totaling 146,247 shares, an increase of 273.6% from the September 30th total of 39,149 shares. Based on an average daily volume of 182,220 shares, the short-interest ratio is presently 0.8 days. Approximately 0.0% of the company's shares are sold short.
Analysts Set New Price Targets
A number of equities analysts have issued reports on MKKGY shares. UBS Group cut Merck KGaA from a "strong-buy" rating to a "hold" rating in a report on Thursday, August 20th. Zacks Research lowered shares of Merck KGaA from a "hold" rating to a "strong sell" rating in a research note on Monday, October 12th. Finally, HSBC upgraded shares of Merck KGaA to a "hold" rating in a report on Monday, July 6th. Five investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Reduce".
View Our Latest Stock Analysis on Merck KGaA
Merck KGaA Stock Up 1.0%
Shares of OTCMKTS MKKGY traded up $0.32 during midday trading on Wednesday, hitting $32.56. 31,423 shares of the stock traded hands, compared to its average volume of 97,241. The company has a market cap of $21.04 billion, a PE ratio of 16.79, a P/E/G ratio of 3.03 and a beta of 0.95. Merck KGaA has a one year low of $23.73 and a one year high of $34.19. The business has a 50 day moving average price of $31.45 and a two-hundred day moving average price of $29.87. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.09 and a current ratio of 1.69.
Merck KGaA Company Profile
(
Get Free Report)
Merck KGaA is a Germany-based science and technology company headquartered in Darmstadt. Founded in 1668, it is one of the world's oldest operating pharmaceutical and chemical companies. The company is separate from Merck & Co, Inc, the U.S.-based pharmaceutical company, and operates as EMD in the United States and Canada.
Merck KGaA conducts its operations through three primary business sectors: Life Science, Healthcare and Electronics. Its Life Science business supplies laboratory products, research tools, bioprocessing technologies and services used by pharmaceutical, biotechnology, academic and industrial customers.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Merck KGaA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Merck KGaA wasn't on the list.
While Merck KGaA currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.
This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.